Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



14 day average Hospitalizations



7 day Average Deaths



Average test positivity past 7 days 12.6%, up 0.6% from last week
Cases have stayed the same from last week but are down from an early December peak
At public test sites in California we have seen an average of 22% positivity over the last few weeks
14 day average hospitalizations have plateaued but are up about 3x from the low in October
7 day average deaths remain at low levels.

- **Turnaround Time (for the week starting 1/1)**
- **89%** of PCR tests TAT< 1 day (down 4% from 93% the previous week)
- **95%** of tests TAT < 2 days (down 4% from 95% the previous week)
- *as of 01/10 -- Source: CalREDIE*

Jan 5 2022 with data as of Jan 3, 2022.
https://covid19.ca.gov/state-dashboard/

Daily new confirmed COVID-19 cases per million people

Our World in Data

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.



COVID-19 cases are rising worldwide in Japan, Hong Kong. In the US and Australia cases are staying steady and in Europe including France cases are steady to falling from a peak.
Waning pop. immunity likely contributed to rise of cases in addition to new immune evasive variants
Highlighting the importance of booster vaccination.

Daily new confirmed COVID-19 deaths per million people

7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.

Our World in Data

LINEAR LOG



Number of COVID-19 patients in hospital per million people

Our World in Data

LINEAR LOG



China situation update

SARSCoV2 Lineages in China

(12/25/22 to 1/5/23)

Nextclade pango	Sequence Count	% of Total
BA.5.2	249	29.93%
BF.7	230	27.64%
BQ.1.22	33	3.97%
Null	31	3.73%
BA.5.2.1	31	3.73%
BQ.1	23	2.76%
BQ.1.1	22	2.64%
XBB.1	16	1.92%
BA.5	16	1.92%
XBC	11	1.32%
BA.5.1	10	1.20%

- Number of sequences in GISAID is still **very low**, but limited data suggests that BA.5 lineages are dominant
- Several sublineages from China have already been proposed, but nothing particularly concerning

https://public.tableau.com/app/profile/raj.rajnarayanan/viz/SARSCoV2Lineages-NextCladePANGO-China/Dashboard1

@RajlabN

Visualization based on data in GISAID, re-analyzed in Nextclade for lineage assignment

Variant update

CDC NOWCAST – Variant Proportions in the US

United States: 10/2/2022 – 1/7/2023



United States: 1/1/2023 – 1/7/2023 NOWCAST

USA

WHO label	Lineage #	US Class	%Total	95%PI	
Omicron	BQ.1.1	VOC	34.4%	26.7-43.0%	-2.3%
	XBB.1.5	VOC	27.6%	14.0-46.5%	+9.3%
	BQ.1	VOC	21.4%	16.1-27.7%	-2.9%
	XBB	VOC	4.9%	4.0-6.1%	-0.4%
	BA.5	VOC	3.7%	2.7-5.0%	-1.7%
	BN.1	VOC	3.0%	2.1-4.1%	-0.3%
	BF.7	VOC	2.2%	1.6-3.0%	-0.8%
	BA.2.75	VOC	1.3%	0.9-2.0%	-0.0%
	BA.5.2.6	VOC	0.7%	0.5-0.9%	-0.2%
	BA.2	VOC	0.3%	0.2-0.5%	-0.1%
	BF.11	VOC	0.3%	0.2-0.4%	-0.1%
	BA.4.6	VOC	0.2%	0.2-0.3%	-0.2%
	BA.2.75.2	VOC	0.1%	0.1-0.1%	-0.0%

- XBB.1.5 continues to increase
- All other lineages decreasing except BA.2.75 which is unchanged in prevalence

XBB.1.5

- XBB.1.5
- Fusion of BA.2.10.1.1 and BA.2.75.3.1.1.1
- Immune evasive, evades monoclonal antibodies
- Paxlovid still works
- Lineage has the greatest increase in growth in the US
- Highest number of cases in New York

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid

- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date



Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date